Table 4.
Parameter | FDC therapy group (n=61) | Olmesartan medoxomil group (n=36) | Rosuvastatin group (n=36) | Placebo group (n=29) |
---|---|---|---|---|
Week 4 | ||||
Total cholesterol, LS mean percent change from baseline (SE), % | −36.1 (1.9) | −1.1 (2.4) | −33.9 (2.4) | −3.5 (2.6) |
LS mean difference, % (SE) (95% CI) | – | −35.0* (2.8) (−40.6 to 29.4) | −2.23*** (2.8) (−7.8 to 3.3) | −32.6* (3.3) (−38.6 to 26.6) |
Triglyceride LS mean percent change from baseline (SE), % | −15.5 (5.6) | 9.5 (7.0) | −8.7 (7.2) | 15.7 (7.9) |
LS mean difference, % (SE) (95% CI) | – | −25.0** (8.6) (−42.0 to 8.1) | −6.8*** (8.6) (−23.9 to 10.3) | −31.2** (9.2) (−49.5 to 13.0) |
HDL-C, LS mean percent change from baseline (SE), % | 8.0 (2.1) | 1.1 (2.7) | 5.8 (2.7) | 6.2 (3.0) |
LS mean difference, % (SE) (95% CI) | – | 6.9** (3.3) (0.5 to 13.3) | 2.2*** (3.3) (−4.2 to 8.6) | 1.8*** (3.5) (−5.1 to 8.6) |
Week 8 | ||||
Total cholesterol, LS mean percent change from baseline (SE), % | −37.1 (2.0) | −0.7 (2.5) | −32.8 (2.6) | −2.4 (2.8) |
LS mean difference, % (SE) (95% CI) | −36.4* (3.0) (−42.3 to 30.1) | −4.35*** (3.0) (−10.3 to 1.6) | −34.7* (3.2) (−41.1 to 28.4) | |
Triglyceride, LS mean percent change from baseline (SE), % | −13.7 (6.4) | 17.8 (8.0) | −8.1 (8.2) | 0.9 (9.0) |
LS mean difference, % (SE) (95% CI) | −31.4** (9.7) (−50.6 to 12.2) | −5.6*** (9.8) (−24.9 to 13.7) | −14.6*** (10.4) (−35.2 to 6.1) | |
HDL-C, LS mean percent change from baseline (SE), % | 6.9 (2.2) | −1.2 (2.8) | 5.3 (2.8) | 9.7 (3.1) |
LS mean difference, % (SE) (95% CI) | 8.1** (3.4) (1.4 to 14.8) | 1.5*** (3.4) (−5.6 to 8.2) | −2.8*** (3.6) (−10.0 to 4.4) |
Notes:
P<0.0001;
P<0.05;
P>0.05 (analysis of covariance) vs FDC therapy.
Abbreviations: CI, confidence interval; FDC, fixed-dose combination; HDL-C, high-density lipoprotein cholesterol; LS, least square; SE, standard error.